Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy (a form of treatment that uses drugs or
other substances to identify and attack specific types of cancer cells with less harm to
normal cells) as a possible treatment for high-risk acute myeloid leukemia.
The names of the study interventions involved in this study are:
- Alisertib / MLN8237
- Cytarabine / Cytosine Arabinoside
- Idarubicin / Idarubicin hydrochloride
- Daunorubicin (Can be used in place of idarubicin)